Precision BioSciencesDTIL
About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Employees: 108
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
10% more funds holding
Funds holding: 51 [Q3] → 56 (+5) [Q4]
4.61% more ownership
Funds ownership: 45.97% [Q3] → 50.58% (+4.61%) [Q4]
51% less capital invested
Capital invested by funds: $29.8M [Q3] → $14.7M (-$15.1M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Patrick Trucchio 14% 1-year accuracy 26 / 187 met price target | 1,028%upside $60 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 5 articles about DTIL published over the past 30 days









